The British General Medical Council revoked the credentials of Tonmoy Sharma in 2008 because of research misconduct. Sharma was an author on studies for which we are corresponding authors (1, 2) and for which Eli Lilly and Company was the sponsor. These papers came from a 14-site comparison of olanzapine and haloperidol for which Sharma directed one site through his position at the Institute of Psychiatry, London. Through reviewing our findings because of this development, we were able to verify that the analyses conducted for the primary manuscript had tested for a center effect and found that it was not significant. Preliminary analyses for the cognition manuscript included examination of the neurocognition composite score, which found no significant differences across sites. Consequently, we do not believe that possible irregularities in the conduct of research at this site change the overall conclusions of these studies.
R.S.E. Keefe, Ph.D.Robert W. Baker, M.D., Eli Lilly and Company
1. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396–1404
2. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA; HGDH Research Group: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985–995